News Articles
Latest articles, insights, and updates from the blog.
Contact Ketamine Troche
Send corrections, provider questions, or advertising inquiries.
FDA Review of Preservative-Free Ketamine Advances
NRx Pharmaceuticals reports progress on FDA review of its preservative-free ketamine application. Here's what it could mean for troche access and compounding.
Ketamine Side Effects: What New Data Means for Troches
New 2026 NMDA-antagonist data on troche side effects and discontinuation rates: how ketamine troches compare on safety and tolerability vs other formats.
NRx's FDA Push for Preservative-Free Ketamine Explained
NRx Pharmaceuticals reports FDA progress on a preservative-free ketamine application. Here's what it means for troche access, compounding, and home dosing.
NMDA Antagonist Side Effects: What Troche Users Should Know
New research compares side effect profiles and dropout rates across NMDA antagonists. Here's what it means for ketamine troche patients in 2026.
BXCL501 PTSD Trial: What It Means for Ketamine Users
A new DoD-backed BXCL501 trial targets acute stress reactions and PTSD prevention. Here's what ketamine troche patients should know.
NMDA Antagonist Side Effects: What Troche Users Need to Know
New clinical guidance on NMDA antagonist side effects and discontinuation rates has direct implications for ketamine troche patients. Here's what it means for your treatment.
Glutamate Pathway Treatments Reshape TRD Care in 2026
New research highlights glutamate-targeting treatments for TRD, including esketamine and ketamine troches. Here's what it means for your care plan.
NMDA Side Effects: What Troche Users Need to Know
New clinical data on NMDA receptor antagonist side effects and dropout rates, and what it means for ketamine troche dosing and monitoring routines.
Insurance Gaps Push Patients to Ketamine Access Funds
Most insurers still deny ketamine coverage for depression. Learn how patient assistance programs are bridging the gap and what it means for troche access.
Esketamine vs. Troches: What TRD Patients Should Know
A new clinical review on esketamine for TRD highlights access barriers and patient preferences, here's what it means for ketamine troche therapy.
Esketamine TRD Access Gaps Open Doors for Troches
New clinician data on esketamine for TRD reveals access barriers that make compounded ketamine troches a practical frontline option for many patients.
France Approves IV Ketamine for Suicidal Crisis: What It Means
France has approved IV ketamine for acute suicidal crises. Here's what this global shift means for ketamine troche patients and at-home treatment access in the U.S.